Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vardenafil for Endothelial Dysfunction in Type 2 Diabetes
NCT02219646Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2010
- Primary completion
- Feb 2013
- Countries
- 1
- Sponsor
- Azienda USL di Modena
- Modality
- Small Molecules
- Drugs
- vardenafil
- Conditions
- endothelial dysfunction
01
Overview
Phase 2, randomised, double-blind trial of vardenafil in endothelial dysfunction (2 arms), sponsored by Azienda USL di Modena. Primary endpoint: Serum Endothelin-1 Levels at 6 months. Started Mar 2010; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Vardenafil
Vardenafil 10 mg twice daily
Control
Placebo twice daily
03
Endpoints
Primary
Serum Endothelin-1 Levels
Secondary
Flow Mediated Dilation
Beyond the preview
Go deeper on NCT02219646.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02219646.